Deciphera Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing medicines to improve the lives of people with cancer. Using its proprietary switch-control kinase inhibitor platform and capabilities in kinase biology, Co. designs kinase inhibitors to target the switch pocket region of the kinase with the goal of developing medicines. QINLOCK, Co.'s switch-control kinase inhibitor, was developed using Co.'s proprietary drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor. Co. has developed a pipeline of drug candidates, including vimseltinib and DCC-3116. The DCPH stock yearly return is shown above.
The yearly return on the DCPH stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the DCPH annual return calculation with any dividends reinvested as applicable (on ex-dates).
|